Mounjaro on the NHS or privately: what the difference actually means for you

The biggest myth: going private means skipping proper clinical oversight

It is easy to assume that the NHS route is the careful, medically supervised one, and that private prescribing is a faster but looser alternative. That is not accurate. Both routes require a prescriber to assess you against the licensed criteria before a single pen is dispensed. The legal framework is identical: Mounjaro (tirzepatide) is a Prescription-Only Medicine under the Human Medicines Regulations 2012, and no pharmacy (NHS or private) may dispense it without a valid prescription following clinical assessment.

What differs is the administrative layer around that clinical decision. NHS access sits inside a phased commissioning structure; a private route removes that queue while keeping the clinical gate firmly in place. At nume, your consultation answers go to a GPhC-registered Independent Prescriber who reads them personally on the day you submit. Photo-ID verification, live weight confirmation on video, GP notification in line with GPhC guidance, and a full medication history check are all part of the process, the same rigour a thoughtful NHS prescriber would apply, without the waiting list attached to it.

The NICE appraisal of tirzepatide (TA1026) notes the clinical evidence base from trials involving thousands of adults, and its recommendations inform both routes. Oversight is not optional on either path. The question is really about access timing and eligibility thresholds.

How NHS eligibility for Mounjaro currently works, and why many people do not qualify yet

NICE recommended tirzepatide for NHS use in December 2024 (TA1026), but implementation is phased. As of mid-2026, NHS access in England requires a BMI of 40 or above plus four or more of five specified conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. Cohort 2 (BMI 35–39.9 plus four or more of those conditions) opened in June 2026. A further cohort covering BMI 40 plus with three conditions is expected around March 2027. Ethnic-background adjustments reduce each BMI threshold by 2.5 kg/m² for relevant groups under NICE's published recommendations.

Even meeting those criteria does not guarantee a prompt appointment. GP practices may prescribe under the 2026/27 contract, but participation is voluntary, so availability varies by surgery and region. Specialist weight-management services that hold existing Wegovy (semaglutide) contracts are separately commissioned. For someone with a BMI of 32 and one weight-related condition, clinically eligible for treatment through a private pharmacy for Mounjaro, the current NHS pathway simply does not have a place for them yet.

Scotland, Wales and Northern Ireland have their own thresholds and commissioning timelines; the position in each nation differs from the England phasing described above. The NHS England overview of weight management injections keeps this updated.

What the private route costs, and what that price actually covers

Private Mounjaro pricing in the UK reflects the cost of the medicine plus the clinical service around it. Eli Lilly adjusted its UK list price significantly from September 2025, reported market prices since then have ranged roughly £149 to £375 per month depending on the dose and provider. Any figure below that range should prompt questions about what is or is not included.

Some private providers quote a medicine price and bill separately for the consultation, the prescription, and delivery. Our approach to private Mounjaro bundles all of it: consultation, prescription, treatment, and free next-working-day tracked delivery in plain unbranded packaging. There are no subscriptions and no auto-renewals, each repeat order is a fresh clinical review. If you want to understand exactly what the process involves before committing, you can read about how to buy Mounjaro online through a regulated pharmacy; worth knowing if you are timing a new pen around payday or returning from holiday and running low.

We are deliberate about not being the cheapest option. For a prescription medicine, the cost of inadequate clinical oversight is not measured in pounds. Verifying any online pharmacy on the GPhC register (our premises number is 9012878) takes about thirty seconds and tells you whether the pharmacy is real, registered, and accountable to a regulator. That check is worth doing before you hand over payment details to anyone.

Side by side: NHS and private Mounjaro at a glance

The table below summarises the key practical differences. Numbers in the eligibility column reflect published NHS England and NICE guidance as of mid-2026; private eligibility reflects the licensed criteria in the Mounjaro SmPC. Refer to the individual sources for the most current position, as NHS commissioning phases are updated periodically.

This comparison covers the clinical and access dimensions; it is not a recommendation. Which route suits your situation (and whether tirzepatide is appropriate for you at all) is a clinical decision. Our prescribers make that assessment with you, individually, at the point of your consultation. If you would like to explore the private route, you can read more about how a private Mounjaro prescription works, find out whether a Mounjaro private clinic is the right setting for your needs, or review the broader weight management treatments we offer. To start, speak to our prescribers through a free consultation, and if you would like further detail on what a private pharmacy clinic for Mounjaro involves before you do, that page sets it out clearly, and we will take it from there.